# TLX catalysts: Telix Pharmaceuticals Ltd PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/tlx/catalysts

> Telix Pharmaceuticals Ltd (TLX) has 13 upcoming catalysts. The next is the ITM-11 interim data readout, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for TLX?

Telix Pharmaceuticals Ltd (TLX) has 13 upcoming catalysts. The next is the ITM-11 interim data readout, 1H 2027. Press release filed with the SEC (EX-99): "ITM-11 has completed a successful Phase 3 trial (COMPETE, NCT03049189)4 and fully enrolled a second indication expansion Phase 3 study (COMPOSE, NCT04919226) with an interim analysis expected in H1 2027." [Calendar and source filings](https://sec-api.dev/companies/tlx/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001628280-26-062813, https://www.sec.gov/Archives/edgar/data/2007191/000162828026062813/a20260921telixitmasxvfin.htm (retrieved 2026-11-12). Last confirmed 2026-09-21. Cite: https://sec-api.dev/companies/tlx/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Telix Pharmaceuticals Ltd |
| Ticker | TLX (Nasdaq) |
| SEC CIK | 2007191 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/tlx |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 17, 2021 | [Gozellix (gallium ga-68 gozetotide) FDA approval](https://sec-api.dev/pdufa/gallium-ga-68-gozetotide) | TLX |  | completed, approved | "NDA214032 ORIG-1 (Type 3 - New Dosage Form and Type 4 - New Combination): submission_status AP, submission_status_date 20211217, review_priority STANDARD; sponsor_name TELIX; product ILLUCCIX (GALLIUM GA-68 GOZETOTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214032%22)) |
| Jan 2022 | [TLX591 trial start](https://sec-api.dev/pdufa/tlx591) | TLX |  | completed | "We dosed the first patient in a Phase 1 trial evaluating the safety and tolerability profile of TLX591 in combination with the standard of care in mCRPC patients in January 2022, which we refer to as the ProstACT SELECT trial." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/2007191/000114036125005562/ef20038762_20f.htm)) |
| March 15, 2023 | [Gozellix (gallium ga-68 gozetotide) label expansion decision](https://sec-api.dev/pdufa/gallium-ga-68-gozetotide) | TLX |  | completed, approved | "NDA214032 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20230315, review_priority STANDARD; sponsor_name TELIX; product ILLUCCIX (GALLIUM GA-68 GOZETOTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214032%22)) |
| Jul 2023 | [TLX250 trial start](https://sec-api.dev/pdufa/tlx250) | TLX | diverse range of solid tumors for potential therapeutic and diagnostic applications | completed | "In June 2023, we dosed the first patient in the Phase 2 STARBURST trial of TLX250-Px exploring CAIX expression in patients with a diverse range of solid tumors for potential therapeutic and diagnostic applications." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm)) |
| Dec 2023 | [TLX250 NDA/BLA submission](https://sec-api.dev/pdufa/tlx250) | TLX |  | completed | "We submitted a BLA for TLX250-Px to the FDA for regulatory approval in December 2023 for characterization of masses as ccRCC." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm)) |
| Jul 2024 | [TLX007 PDUFA date](https://sec-api.dev/pdufa/tlx007) | TLX |  | scheduled | "We have also submitted a new drug application, or NDA, to the FDA for TLX007-CDx for the imaging of prostate cancer, which was accepted by the FDA in July 2024 and assigned a Prescription Drug User Fee Action, or PDUFA, goal date of March 24," ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/2007191/000114036125005562/ef20038762_20f.htm)) |
| Aug 2024 | [TLX101 NDA/BLA submission](https://sec-api.dev/pdufa/tlx101) | TLX |  | completed | "In August 2024, we submitted a NDA for TLX101-Px for the characterization of progressive or recurrent glioma from treatment related changes in both adult and pediatric patients." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm)) |
| Oct 2024 | [TLX101 PDUFA date](https://sec-api.dev/pdufa/tlx101) | TLX |  | scheduled | "In October 2024, the FDA accepted the NDA, granted priority review and assigned a PDUFA goal date of April" ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/tlx-20251231.htm)) |
| Oct 2024 | [TLX101 NDA/BLA acceptance](https://sec-api.dev/pdufa/tlx101) | TLX |  | completed | "In October 2024, the FDA accepted the New Drug Application ("NDA"), and granted priority review and assigned a Prescription Drug User Fee Act ("PDUFA"), goal date of April 26, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm)) |
| Nov 2024 | [TLX250 trial start](https://sec-api.dev/pdufa/tlx250) | TLX | ccRCC | completed | "In November 2024, we dosed the first patient in the Phase 3 ZIRCON-CP study of TLX250-Px PET imaging of ccRCC in Chinese patients." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm)) |
| Dec 2024 | [TLX250 NDA/BLA submission](https://sec-api.dev/pdufa/tlx250) | TLX |  | completed | "In December 2024 we resubmitted our BLA to the FDA for TLX250-Px, and the" ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/tlx-20251231.htm)) |
| Dec 2024 | [TLX250 NDA/BLA acceptance](https://sec-api.dev/pdufa/tlx250) | TLX |  | completed | "In December 2024 we resubmitted our BLA to the FDA for TLX250-Px, and the FDA accepted our application in February 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm)) |
| December 27, 2024 | [Girentuximab NDA/BLA submission](https://sec-api.dev/pdufa/girentuximab) | TLX |  | completed | "Kidney cancer imaging, TLX250-CDx (Zircaix®4, 89Zr-girentuximab): Telix submitted a Biologics License Application (BLA) for its renal cancer imaging candidate on 27 December 2024 and continues to target a U.S. commercial launch in H2 20255." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000200719125000007/q4bizupdate.htm)) |
| 1H 2025 | [Rosopatamab topline data readout](https://sec-api.dev/pdufa/rosopatamab) | TLX |  | scheduled | "ProstACT™ Global, the Phase 3 trial of TLX591 (177Lu-rosopatamab tetraxetan), Telix's prostate cancer therapy candidate, continues to recruit and remains on track to deliver a Part 1 readout (safety and dosimetry) in H1 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000200719125000047/q1bizupdate.htm)) |
| Mar 2025 | [Vipivotide FDA approval](https://sec-api.dev/pdufa/vipivotide) | TLX |  | completed, approved | "In March 2025, Pluvicto was approved by the FDA for earlier use prior to chemotherapy, in PSMA-positive mCRPC." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm)) |
| March 20, 2025 | [TLX007 FDA approval](https://sec-api.dev/pdufa/tlx007) | TLX |  | completed, approved | "Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Gozellix® (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix's next-generation PSMA-PET imaging1 agent for prostate cancer." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000200719125000037/gozpr.htm)) |
| March 20, 2025 | [Gozellix (gallium ga-68 gozetotide) FDA approval](https://sec-api.dev/pdufa/gallium-ga-68-gozetotide) | TLX |  | completed, approved | "NDA219592 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20250320, review_priority STANDARD; sponsor_name TELIX INNOVATIONS; product GOZELLIX (GALLIUM GA-68 GOZETOTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219592%22)) |
| March 21, 2025 | [Gozellix (gozellix) FDA approval](https://sec-api.dev/pdufa/gozellix) | TLX |  | completed, approved | "On 21 March 2025, the FDA approved the New Drug Application (NDA) for Gozellix®11, Telix's next-generation PSMA-PET imaging agent for prostate cancer that provides a longer shelf life of up to six hours and an extended distribution radius compared to existing gallium-based imaging products." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000200719125000047/q1bizupdate.htm)) |
| March 24, 2025 | [TLX007 PDUFA date](https://sec-api.dev/pdufa/tlx007) | TLX |  | completed, approved | "In July 2024, the FDA accepted the NDA for TLX007-CDx and assigned a PDUFA goal date of March 24, 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/2007191/000114036125005562/ef20038762_20f.htm)) |
| Apr 2025 | [TLX300 trial start](https://sec-api.dev/pdufa/tlx300) | TLX |  | completed | "In April 2025, we dosed the first patient in ZOLAR, a first-in-human Phase 1 proof-of-concept targeting and biodistribution trial using TLX300-Px." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm)) |
| Apr 2025 | [TLX101 trial start](https://sec-api.dev/pdufa/tlx101) | TLX |  | completed | "TLX101-Tx was investigated in the recurrent setting in the investigator-initiated IPAX-Linz Phase 2 trial, which reported preliminary results in April 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm)) |
| April 25, 2025 | [Pixclara (floretyrosine f-18) complete response letter (CRL)](https://sec-api.dev/pdufa/floretyrosine-f-18) | TLX |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA218592_20250425.pdf%22)) |
| April 26, 2025 | [TLX101 PDUFA date](https://sec-api.dev/pdufa/tlx101) | TLX |  | completed, complete response letter | "The NDA for TLX101-CDx (Pixclara®15, 18F-floretyrosine or 18F-FET), Telix's brain cancer imaging candidate, continues to progress with a PDUFA goal date of 26 April 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000200719125000047/q1bizupdate.htm)) |
| April 27, 2025 | [TLX101 complete response letter (CRL)](https://sec-api.dev/pdufa/tlx101) | TLX |  | completed, complete response letter | "Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that it has received a Complete Response Letter (CRL) from the United States (U.S.) Food and Drug Administration (FDA) for its New Drug Application (NDA) for TLX101-CDx (Floretyrosine F18 or 18F-FET, Pixclara®1), an investigational agent for the imaging of glioma, a rare and life-threatening brain cancer." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000200719125000049/pixpr.htm)) |
| May 9, 2025 | [Telix Pharmaceuticals Ltd primary completion](https://sec-api.dev/companies/tlx/catalysts) | TLX | Cervical Cancer; Colorectal Cancer; Esophageal Cancer | withdrawn | "NCT05563272 (89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-05-09 (ACTUAL); Lead Sponsor Telix Pharmaceuticals (Innovations) Pty Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05563272)) |
| Jun 2025 | [Besilesomab trial start](https://sec-api.dev/pdufa/besilesomab) | TLX |  | completed | "In June 2025, the first patient was dosed in a Phase 2 IIT in pediatric high-risk leukemia." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm)) |
| 2H 2025 | [TLX592 trial start](https://sec-api.dev/pdufa/tlx592) | TLX |  | scheduled | "We plan to initiate a Phase 1/2 trial designed to evaluate the safety profile of 225Ac-labelled TLX592 in the second half of 2025, subject to regulatory approval." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/2007191/000114036125005562/ef20038762_20f.htm)) |
| July 1, 2025 | [Telix Pharmaceuticals Ltd primary completion](https://sec-api.dev/companies/tlx/catalysts) | TLX | Metastatic Prostate Cancer | withdrawn | "NCT04876651 (The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-07-01 (ACTUAL); Lead Sponsor Telix Pharmaceuticals (Innovations) Pty Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04876651)) |
| Aug 2025 | [Girentuximab complete response letter (CRL)](https://sec-api.dev/pdufa/girentuximab) | TLX |  | completed, complete response letter | "Zircaix® (TLX250-Px, 89Zr-DFO-girentuximab): Participated in two Type A meetings with the FDA to address deficiencies identified in the CRL received in August 2025 for Telix's ccRCC PET imaging candidate16." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm)) |
| August 4, 2025 | [TLX250 complete response letter (CRL)](https://sec-api.dev/pdufa/tlx250) | TLX |  | completed, complete response letter | "In August 2025, the FDA issued a Complete Response Letter ("CRL"), citing deficiencies relating to the Chemistry, Manufacturing, and Controls ("CMC") package." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm)) |
| August 27, 2025 | [Girentuximab PDUFA date](https://sec-api.dev/pdufa/girentuximab) | TLX |  | scheduled | "The FDA accepted the Biologics License Application (BLA) for Telix's kidney cancer imaging candidate TLX250-CDx (Zircaix®15, 89Zr-DFO-girentuximab), granted a Priority Review, and provided a PDUFA16 goal date of 27 August 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000200719125000047/q1bizupdate.htm)) |
| Oct 2025 | [TLX090 trial start](https://sec-api.dev/pdufa/tlx090) | TLX |  | completed | "In October 2025, we dosed the first patient in a Phase 1 clinical trial of TLX090-Tx called SOLACE (Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage bone pain)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm)) |
| December 7, 2025 | [TLX591 trial start](https://sec-api.dev/pdufa/tlx591) | TLX | metastatic castration resistant prostate cancer | completed | "Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in Part 2 (randomized treatment expansion) of its ProstACT Global Phase 3 study evaluating its lead prostate cancer therapy candidate TLX591 (lutetium (177Lu) rosopatamab tetraxetan) in patients with metastatic castration resistant prostate cancer (mCRPC)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000200719125000073/prostactpr.htm)) |
| December 2025 | [68ga-psma-11 primary completion](https://sec-api.dev/pdufa/68ga-psma-11) | TLX |  | delayed | "NCT05847348 (68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients): Overall Status UNKNOWN; Phase PHASE3; Primary Completion 2025-12-30 (ESTIMATED); Lead Sponsor Telix Pharmaceuticals (Innovations) Pty Limited." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05847348)) |
| April 10, 2026 | [Bla761401 complete response letter (CRL)](https://sec-api.dev/pdufa/bla761401) | TLX |  | completed, complete response letter | "We have completed our review of this application and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761401_20260410.pdf%22)) |
| June 2026 | [89zr-tlx250 pet/ct primary completion](https://sec-api.dev/pdufa/89zr-tlx250-pet-ct) | TLX | Clear Cell Renal Cell Carcinoma | delayed | "NCT06750419 (89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-06-30 (ESTIMATED); Lead Sponsor Telix Pharmaceuticals (Innovations) Pty Limited." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06750419)) |
| August 7, 2026 | [ITM-11 complete response letter (CRL)](https://sec-api.dev/pdufa/itm-11) | TLX |  | completed, complete response letter | "ITM-11 U.S. regulatory status CRL received on August 7, 2026 is limited to CMC and third-party facility items and no clinical or nonclinical deficiencies were identified CRL scope FDA cited Chemistry, Manufacturing and Controls (CMC) and third-party commercial facility inspection- related items Clinical package No clinical safety or efficacy issues were identified, and no additional clinical or nonclinical data were requested Remediation ITM is reviewing the feedback and coordinating with relevant external parties to address the cited items Resubmission ITM intends to resubmit the NDA to complete FDA review; timing remains subject to remediation and agency interaction." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000162828026068291/a20261030tlxnoticeofgene.htm)) |
| September 11, 2026 | [TLX400 PDUFA date](https://sec-api.dev/pdufa/tlx400) | TLX |  | scheduled | "Solutions TLX591-Tx for mCRPC, ProstACT Global Part 1 data readout Part 2 international site expansion, interim analysis1 TLX250-Tx for ccRCC, LUTEON, open for recruitment TLX090-Tx for metastatic bone pain, SOLACE, enrollment completion TLX592-Tx for mCRPC, AlphaPRO, patient dosing TLX102-Tx for recurrent GBM and leptomeningeal disease, trial commencement TLX252-Tx for ccRCC and other CAIX-expressing tumors, trial commencement TLX400-Tx recommencement of clinical activity Pixclara2 NDA resubmission (U.S.) accepted, PDUFA goal date September 11, 2026 Zircaix2 BLA resubmission (U.S.) Illuccix, Gozellix BiPASS™ enrollment completion Illuccix Japan trial, enrollment completion Illuccix" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000114036126014495/ef20070387_ex99-2.htm)) |
| September 11, 2026 | [TLX400 NDA/BLA submission](https://sec-api.dev/pdufa/tlx400) | TLX |  | scheduled | "Solutions TLX591-Tx for mCRPC, ProstACT Global Part 1 data readout Part 2 international site expansion, interim analysis1 TLX250-Tx for ccRCC, LUTEON, open for recruitment TLX090-Tx for metastatic bone pain, SOLACE, enrollment completion TLX592-Tx for mCRPC, AlphaPRO, patient dosing TLX102-Tx for recurrent GBM and leptomeningeal disease, trial commencement TLX252-Tx for ccRCC and other CAIX-expressing tumors, trial commencement TLX400-Tx recommencement of clinical activity Pixclara2 NDA resubmission (U.S.) accepted, PDUFA goal date September 11, 2026 Zircaix2 BLA resubmission (U.S.) Illuccix, Gozellix BiPASS™ enrollment completion Illuccix Japan trial, enrollment completion Illuccix" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000114036126014495/ef20070387_ex99-2.htm)) |
| September 11, 2026 | [Pixclara (floretyrosine f-18) FDA approval](https://sec-api.dev/pdufa/floretyrosine-f-18) | TLX |  | completed, approved | "Pixclara \| floretyrosine F 18 \| 9/11/2026 \| To use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change in conjunction with other diagnostic evaluations" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| September 14, 2026 | [Pixclara (pixclara) FDA approval](https://sec-api.dev/pdufa/pixclara) | TLX |  | completed, approved | "Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Pixclara® (floretyrosine F 18 or 18F-FET), an amino acid positron emission tomography (PET) drug for imaging gliomas (brain cancer)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000162828026061892/pixclaraapprovalvfinal.htm)) |
| 1H 2027 | [ITM-11 interim data readout](https://sec-api.dev/pdufa/itm-11) | TLX |  | scheduled | "ITM-11 has completed a successful Phase 3 trial (COMPETE, NCT03049189)4 and fully enrolled a second indication expansion Phase 3 study (COMPOSE, NCT04919226) with an interim analysis expected in H1 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000162828026062813/a20260921telixitmasxvfin.htm)) |
| January 2027 | [68ga-psma-11 primary completion](https://sec-api.dev/pdufa/68ga-psma-11) | TLX | PCA; Prostate Cancer; Prostatic Neoplasm | scheduled | "NCT07052214 (PSMA PET Combined With MRI for the Detection of PCa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor Telix Pharmaceuticals (Innovations) Pty Limited." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07052214)) |
| Jan to Apr 2027 | [68ga-psma-11 topline data readout](https://sec-api.dev/pdufa/68ga-psma-11) | TLX | PCA; Prostate Cancer; Prostatic Neoplasm | scheduled | "NCT07052214 (PSMA PET Combined With MRI for the Detection of PCa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor Telix Pharmaceuticals (Innovations) Pty Limited." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07052214)) |
| Aug to Nov 2027 | [Telix Pharmaceuticals Ltd topline data readout](https://sec-api.dev/companies/tlx/catalysts) | TLX | ccRCC; Renal Cell Carcinoma (Kidney Cancer); Renal Cell Carcinoma (RCC) | scheduled | "NCT07197580 (Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08-31 (ESTIMATED); Lead Sponsor Telix Pharmaceuticals (Innovations) Pty Limited." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07197580)) |
| August 2027 | [Telix Pharmaceuticals Ltd primary completion](https://sec-api.dev/companies/tlx/catalysts) | TLX | ccRCC; Renal Cell Carcinoma (Kidney Cancer); Renal Cell Carcinoma (RCC) | scheduled | "NCT07197580 (Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08-31 (ESTIMATED); Lead Sponsor Telix Pharmaceuticals (Innovations) Pty Limited." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07197580)) |
| December 2027 | [177lu-tlx591 primary completion](https://sec-api.dev/pdufa/177lu-tlx591) | TLX | Metastatic Castration-resistant Prostate Cancer | scheduled | "NCT06520345 (The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Telix Pharmaceuticals (Innovations) Pty Limited." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06520345)) |
| Dec 2027 to Mar 2028 | [177lu-tlx591 topline data readout](https://sec-api.dev/pdufa/177lu-tlx591) | TLX | Metastatic Castration-resistant Prostate Cancer | scheduled | "NCT06520345 (The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Telix Pharmaceuticals (Innovations) Pty Limited." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06520345)) |
| April 2028 | [Floretyrosine f 18 ([18f]fet) primary completion](https://sec-api.dev/pdufa/floretyrosine-f-18-18f-fet) | TLX | Brain Metastasis; Radiation Necrosis; Pseudoprogression | scheduled | "NCT07931261 ([18F]FET PET for Differentiating Tumor Progression vs Treatment-Related Changes in Brain Metastases): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Telix Pharmaceuticals (Innovations) Pty Limited." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07931261)) |
| Apr to Jul 2028 | [Floretyrosine f 18 ([18f]fet) topline data readout](https://sec-api.dev/pdufa/floretyrosine-f-18-18f-fet) | TLX | Brain Metastasis; Radiation Necrosis; Pseudoprogression | scheduled | "NCT07931261 ([18F]FET PET for Differentiating Tumor Progression vs Treatment-Related Changes in Brain Metastases): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Telix Pharmaceuticals (Innovations) Pty Limited." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07931261)) |
| July 2028 | [Tlx-101-tx + lomustine primary completion](https://sec-api.dev/pdufa/tlx-101-tx-lomustine) | TLX | Neoplastic Disease; Glioblastoma; Glioblastoma (GBM) | scheduled | "NCT07100730 (Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Telix Pharmaceuticals (Innovations) Pty Limited." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07100730)) |
| Jul to Oct 2028 | [Tlx-101-tx + lomustine topline data readout](https://sec-api.dev/pdufa/tlx-101-tx-lomustine) | TLX | Neoplastic Disease; Glioblastoma; Glioblastoma (GBM) | scheduled | "NCT07100730 (Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Telix Pharmaceuticals (Innovations) Pty Limited." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07100730)) |
| Dec 2028 to Mar 2029 | [177lu-tlx250 topline data readout](https://sec-api.dev/pdufa/177lu-tlx250) | TLX | ccRCC; Renal Cell Carcinoma (Kidney Cancer); Renal Cell Carcinoma (RCC) | scheduled | "NCT07870746 (Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-12-31 (ESTIMATED); Lead Sponsor Telix Pharmaceuticals (Innovations) Pty Limited." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07870746)) |
| December 2028 | [177lu-tlx250 primary completion](https://sec-api.dev/pdufa/177lu-tlx250) | TLX | ccRCC; Renal Cell Carcinoma (Kidney Cancer); Renal Cell Carcinoma (RCC) | scheduled | "NCT07870746 (Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-12-31 (ESTIMATED); Lead Sponsor Telix Pharmaceuticals (Innovations) Pty Limited." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07870746)) |

## Drugs

- [177lu-tlx250](https://sec-api.dev/pdufa/177lu-tlx250): ccRCC
- [177lu-tlx591](https://sec-api.dev/pdufa/177lu-tlx591): Metastatic Castration-resistant Prostate Cancer
- [68ga-psma-11](https://sec-api.dev/pdufa/68ga-psma-11): Biochemical Recurrence of Malignant Neoplasm of Prostate, PCA
- [89zr-tlx250 pet/ct](https://sec-api.dev/pdufa/89zr-tlx250-pet-ct): Clear Cell Renal Cell Carcinoma
- [Besilesomab](https://sec-api.dev/pdufa/besilesomab): 
- [Bla761401](https://sec-api.dev/pdufa/bla761401): 
- [Pixclara (floretyrosine f-18)](https://sec-api.dev/pdufa/floretyrosine-f-18): 
- [Floretyrosine f 18 ([18f]fet)](https://sec-api.dev/pdufa/floretyrosine-f-18-18f-fet): Brain Metastasis
- [Gozellix (gallium ga-68 gozetotide)](https://sec-api.dev/pdufa/gallium-ga-68-gozetotide): 
- [Girentuximab](https://sec-api.dev/pdufa/girentuximab): 
- [Gozellix (gozellix)](https://sec-api.dev/pdufa/gozellix): 
- [ITM-11](https://sec-api.dev/pdufa/itm-11): 
- [Pixclara (pixclara)](https://sec-api.dev/pdufa/pixclara): 
- [Rosopatamab](https://sec-api.dev/pdufa/rosopatamab): 
- [Tlx-101-tx + lomustine](https://sec-api.dev/pdufa/tlx-101-tx-lomustine): Neoplastic Disease
- [TLX007](https://sec-api.dev/pdufa/tlx007): 
- [TLX090](https://sec-api.dev/pdufa/tlx090): 
- [TLX101](https://sec-api.dev/pdufa/tlx101): 
- [TLX250](https://sec-api.dev/pdufa/tlx250): diverse range of solid tumors for potential therapeutic and diagnostic applications, ccrcc
- [TLX300](https://sec-api.dev/pdufa/tlx300): 
- [TLX400](https://sec-api.dev/pdufa/tlx400): 
- [TLX591](https://sec-api.dev/pdufa/tlx591): metastatic castration resistant prostate cancer
- [TLX592](https://sec-api.dev/pdufa/tlx592): 
- [Vipivotide](https://sec-api.dev/pdufa/vipivotide): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/tlx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TLX catalysts: Telix Pharmaceuticals Ltd PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/tlx/catalysts

```bibtex
@misc{secapidev_companies_tlx_catalysts_20261116,
  title        = {TLX catalysts: Telix Pharmaceuticals Ltd PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/tlx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_tlx_catalysts_20261116","title":"TLX catalysts: Telix Pharmaceuticals Ltd PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/tlx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
